A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors

Trial ID or NCT#

NCT00708006

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects with advanced solid tumors and to determine a phase 2 dose.

Official Title

A Phase 1 Dose-Escalation Study to Evaluate the Safety and Tolerability of HGS1029 (AEG40826-2HCl) in Patients With Advanced Solid Tumors

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * Confirmed advanced solid malignancy* Life expectancy of at least 3 months* Age 18 years or older* Acceptable liver function* Acceptable renal function* Acceptable hematologic status
Exclusion Criteria:
  1. * Received investigational (not yet approved by a regulatory authority)agent within 4 weeks before enrollment.* Received non-investigational agent within 3 weeks before enrollment.* Progressive CNS involvement including the need of corticosteroids* Pregnant or breast-feeding women* Active, uncontrolled bacterial, viral, or fungal infections within 2 weeks of Cycle 1 Day 1* Known HIV infection
View All Criteria
Show Less

Investigator(s)

Branimir I Sikic

Contact us to find out if this trial is right for you.

Contact

Cancer Clinical Trials Office
650-498-7061

View on ClinicalTrials.gov